GB201617092D0 - No details - Google Patents

No details

Info

Publication number
GB201617092D0
GB201617092D0 GBGB1617092.0A GB201617092A GB201617092D0 GB 201617092 D0 GB201617092 D0 GB 201617092D0 GB 201617092 A GB201617092 A GB 201617092A GB 201617092 D0 GB201617092 D0 GB 201617092D0
Authority
GB
United Kingdom
Prior art keywords
details
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB1617092.0A
Other versions
GB2544630A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
WWK Trust
Original Assignee
WWK Trust
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by WWK Trust filed Critical WWK Trust
Publication of GB201617092D0 publication Critical patent/GB201617092D0/en
Publication of GB2544630A publication Critical patent/GB2544630A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GB1617092.0A 2015-11-19 2015-11-19 Combinations for the treatment of dementia, and the enhancement of cognitive function Withdrawn GB2544630A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2015/053526 WO2017085437A1 (en) 2015-11-19 2015-11-19 Combinations for the treatment of dementia, and the enhancement of cognitive function

Publications (2)

Publication Number Publication Date
GB201617092D0 true GB201617092D0 (en) 2016-11-23
GB2544630A GB2544630A (en) 2017-05-24

Family

ID=54704023

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1617092.0A Withdrawn GB2544630A (en) 2015-11-19 2015-11-19 Combinations for the treatment of dementia, and the enhancement of cognitive function

Country Status (2)

Country Link
GB (1) GB2544630A (en)
WO (1) WO2017085437A1 (en)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT784476E (en) 1994-10-05 2003-03-31 Cari Loder TREATMENT OF MULTIPLE SCLEROSIS (EM) AND OTHER DEMELINIZING CONDITIONS USING LOFEPRAMINE IN COMBINATION WITH L-PHENYLALANINE TYROSINE OR TRIPTOFAN AND OPTIONALLY A COMPOUND OF VITAMIN B 12
EP0726073A3 (en) * 1995-02-10 1998-07-08 Eduardo Samuel Bleiweiss Pharmaceutical compositions containing at least one of haloperidol, imipramine or trifluoroperazine
EP0942751B1 (en) * 1996-07-05 2002-09-25 The WWK Trust Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin b12 and/or precursors or inducers of a neurotransmitter
GB0326477D0 (en) * 2003-11-13 2003-12-17 Shs Int Ltd Medicaments for use in promoting and maintaining abstinence
US20060039890A1 (en) * 2004-08-20 2006-02-23 Renshaw Perry F Treatment of psychological and cognitive disorders using a cholesterol -lowering agent in combination with an antidepressant
US8597640B2 (en) * 2007-10-31 2013-12-03 University Of Massachusetts Lowell Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging
EP2624821B1 (en) * 2010-10-07 2018-06-27 Eaglepharma Pty Ltd Combination therapy for the treatment of depression and other non-infectious diseases
US20130064804A1 (en) * 2011-09-14 2013-03-14 Naidu Lp BIO-REPLENISHMENT (BioRep) FOR IMPROVING SLEEP ARCHITECTURE
HRPK20140128B3 (en) * 2014-02-10 2016-10-21 Maja Novak Food supplement and production process therefor

Also Published As

Publication number Publication date
GB2544630A (en) 2017-05-24
WO2017085437A1 (en) 2017-05-26

Similar Documents

Publication Publication Date Title
GB201707959D0 (en) No details
DK3256579T3 (en) Cysteinprotease
DK3256580T3 (en) Cysteinprotease
DK3250592T3 (en) Anti-transthyretin-antistoffer
GB201706130D0 (en) No details
GB201612542D0 (en) no details
GB201615071D0 (en) No details
DK3380145T3 (en) Injektionsapparat
GB201709180D0 (en) No details
DK3272750T3 (en) Morphinan-derivat
AU361999S (en) Ballustrade
GB201616225D0 (en) No details
GB201601250D0 (en) No details present
DK3133099T3 (en) Polymermodificeret polyoldispersion
DK3250312T3 (en) Urea-metalnitrat-scr-system
GB201708207D0 (en) No details
GB201702336D0 (en) No details
GB201614498D0 (en) No details
AU5516P (en) LEP08 Lepidosperma squamatum
GB201521840D0 (en) No details
GB201617092D0 (en) No details
AU5511P (en) PTK647 Epichloe coenophiala
GB201711819D0 (en) No details
AU366552S (en) Nutblock
GB201522111D0 (en) Balaclavas

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)